Cart
sales@molnova.com
Dabrafenib Mesylate
CAS No. 1195768-06-9
Dabrafenib Mesylate( GSK2118436 Mesylate,GSK 2118436B )
Catalog No. M22046 CAS No. 1195768-06-9
Dabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 54 | In Stock |
|
| 5MG | 38 | In Stock |
|
| 10MG | 54 | In Stock |
|
| 25MG | 68 | In Stock |
|
| 50MG | 79 | In Stock |
|
| 100MG | 109 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 221 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDabrafenib Mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionDabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
-
DescriptionDabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).In human endothelial cells, Dabrafenib inhibits the release of HMGB1 and down-regulates the HMGB1-dependent inflammatory response by enhancing the expression of cell adhesion molecules (CAM).
-
In Vitro——
-
In Vivo——
-
SynonymsGSK2118436 Mesylate,GSK 2118436B
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research AreaCancer
-
IndicationLow Grade Glioma (LGG) of Brain With BRAF AberrationHigh Grade Glioma (HGG) of the Brain With BRAF AberrationLow Grade Glioma of Brain With Neurofibromatosis Type 1
Chemical Information
-
CAS Number1195768-06-9
-
Formula Weight615.67
-
Molecular FormulaC24H24F3N5O5S3
-
Purity>98% (HPLC)
-
SolubilityDMSO:34 mg/mL (55.22 mM)
-
SMILESCS(O)(=O)=O.CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.
molnova catalog
related products
-
I-49 free base
I-49 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
-
CCT196969
CCT196969 is a potent, orally bioavailable pan-RAF inhibitor with IC50 of 100, 40 and 12 nM for B-Raf, B-Raf V600E and C-Raf, respectively.
-
EBI-907
EBI-907 is a highly potent, selective, orally active B-Raf V600E inhibitor with enzyme IC50 of 7 nM, A375 cell growth IC50 of 13 nM.
